Effectiveness of Canakinumab for first line steroid free treatment in systemic juvenile idiopathic arthritis - report from EULAR2024

from Medical Digest & Congress Report · host Medical Congress News

Professor Gerd Horneff explains the results of a late breaking abstract from EULAR 2024, effectiveness of canakinumab for first line steroid free treatment in systemic onset juvenile idiopathic arthritis/ juvenile Still’s disease. Video: https://medicaldigest.org/scientific-contents/interview:what-new-osteoporosis-rheumatology

Episode metadata supplied by the publisher feed · Published Jun 21, 2024

Embed this episode

Attribution link and audio player

NOW PLAYING

Effectiveness of Canakinumab for first line steroid free treatment in systemic juvenile idiopathic arthritis - report from EULAR2024

0:00 5:48

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Medical Digest & Congress Report?

This episode is 5 minutes long.

When was this Medical Digest & Congress Report episode published?

This episode was published on June 21, 2024.

Can I download this Medical Digest & Congress Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!